Technology Boom in Wound Closure Products Offers New Promise For Reducing Trauma While peeding Up Recovery

The wound closure device market is characterized by a wide range of competing technologies from traditional sutures to the latest tissue adhesives. While trauma wounds as well as surgical wounds require closure, technological advancement is aimed primarily at addressing surgical wound closure. The products aim to reduce infection rates, provide effective hemostasis, provide a microbial barrier and promote faster healing as well as being easier to administer. A general shift toward minimally invasive procedures presents new challenges for wound closure include vascular sealing and tissue closure.

According to Marketstrat Inc., the wound closure market is growing worldwide at a CAGR of almost 6 percent. This market, currently estimated to be just over $6.3 billon is generating new demand due to growing rates of surgical procedures. High growth product segments are hemostats and tissue adhesives/ sealants. Soaring rates of surgical procedures worldwide, in particular vascular procedures and endoscopic procedures are creating demand for easy to-use, biocompatible, fast-acting and more efficacious closure agents. According to the Marketstrat report entitled, ‘Wound Closure Products
Markets Worldwide’, China’s emerging healthcare infrastructure will soon lead to one of the fastest growing markets for wound closure products.

Innovative products have been developed in every wound closure product category. Some of the recently introduced products include:

Hemostats

a) OMNEX™ Surgical Sealant (Ethicon) – vascular reconstructions also has adjunctive hemostatic properties. Ethicon reports that clinical trials indicate a hemostatic rate that is three times faster than oxidized regenerated cellulose.

b) PerClot from CryoLife – is a synthetic absorbable modified polymer (AMP®) for use as a hemostat in surgical procedures or following traumatic injuries.

Sutures

a) The V-loc 90 and 180 knotless wound closure device from Covidien speed up suturing by eliminating the need for knot-tying.

Read More

BPH and Prostate Cancer in the Baby Boomer Generation: New Treatments Offering Reduced Risk of Incontinence and Impotence are Available

A wave of technologically advanced, minimally invasive devices introduced over the last decade or so, has transformed the landscape of the prostate surgery.  It is expected that the incidence of BPH and prostate cancer will increase in parallel to the rising population of men over 50 across the globe.  The worldwide market for minimally invasive prostate surgery and treatment devices is estimated to reach almost $1.38 billion by the end of 2011, according to a new report released by Marketstrat Inc. of Pleasanton, CA.

For details on the BPH Prostate report, click here

BPH treatment has begun to shift away from TURP towards a whole host of new options for ablation and removal of prostatic tissue, based on microwave energy (transurethral microwave therapy or TUMT), radio-frequency waves (transurethral needle  ablation or TUNA) and lasers (holmium and greenlight/KTP, i.e. potassium-titanyl-phosphate).  The main aim of these technologies has been to reduce the common side-effects of prostate surgery, namely incontinence and impotence, while ensuring more precise delivery of energy to the target tissue.  According to Marketstrat Inc., demand for all these options will continue due to the wide variation in symptoms of men presenting with BPH.  Demand for Greenlight laser photoselective vaporization, or PVP, will far exceed others, with a cumulative average growth rate (CAGR) of over 9 percent over the 2009 to 2017 period.  American Medical Systems is the sole provider of this technology in the US.   Read More

BPH and Prostate Cancer in the Baby Boomer Generation: New Treatments Offering Reduced Risk of Incontinence and Impotence are Available

A wave of technologically advanced, minimally invasive devices introduced over the last decade or so, has transformed the landscape of the prostate surgery.  It is expected that the incidence of BPH and prostate cancer will increase in parallel to the rising population of men over 50 across the globe.  The worldwide market for minimally invasive prostate surgery and treatment devices is estimated to reach almost $1.38 billion by the end of 2011, according to a new report released by Marketstrat Inc. of Pleasanton, CA.

For details on the BPH Prostate report, click here

BPH treatment has begun to shift away from TURP towards a whole host of new options for ablation and removal of prostatic tissue, based on microwave energy (transurethral microwave therapy or TUMT), radio-frequency waves (transurethral needle  ablation or TUNA) and lasers (holmium and greenlight/KTP, i.e. potassium-titanyl-phosphate).  The main aim of these technologies has been to reduce the common side-effects of prostate surgery, namely incontinence and impotence, while ensuring more precise delivery of energy to the target tissue.  According to Marketstrat Inc., demand for all these options will continue due to the wide variation in symptoms of men presenting with BPH.  Demand for Greenlight laser photoselective vaporization, or PVP, will far exceed others, with a cumulative average growth rate (CAGR) of over 9 percent over the 2009 to 2017 period.  American Medical Systems is the sole provider of this technology in the US.   Read More